U.S. Ambassador Mark Brzezinski Visits Scope Fluidics

17-08-2023

Scope Fluidics S.A. (GPW: SCP) – a biotechnology company listed in the sWIG80 index, operating under the Venture Studio model, had the honor of hosting U.S. Ambassador to the United States of America, Mark Brzezinski, at its headquarters. The U.S. Ambassador met with the Scope Fluidics team and familiarized himself with the process of developing the company’s groundbreaking new technologies.

Mark Brzezinski, U.S. Ambassador, remarked:

“I am delighted to have the opportunity today to witness up close how medical diagnostic technologies are being developed at Scope Fluidics. Poland is creating a high-tech ecosystem, and I see great potential for collaboration between Poland and the United States in this field. I eagerly anticipate further instances of fruitful exchange between American and Polish businesses, especially in the crucial area of healthcare, which holds such importance for our societies.”

Piotr Garstecki, Co-founder, significant shareholder, and CEO of Scope Fluidics, stated:

“It is an immense pleasure and honor for us to host Ambassador Brzezinski at Scope Fluidics. Collaboration with American companies is of great significance to us – the American healthcare, technology, and innovation markets play a key global role. We are pleased that the PCR|ONE technology has found capable hands in the American company Bio-Rad and that our collaboration with American entities is growing stronger.”

As part of the visit, the U.S. Ambassador had the opportunity to meet with members of the Scope Fluidics team and gain insight into the development process of the company’s technologies. The visit program also included a presentation of the BacterOMIC system.

About Scope Fluidics

Scope Fluidics S.A., headquartered in Warsaw, is a biotechnology company listed in the sWIG80 index, focusing on innovative solutions utilizing microfluidic technologies for applications in molecular diagnostics for the medical diagnostics and healthcare market.

Scope Fluidics has developed the BacterOMIC system for automated antibiotic resistance analysis to enable the selection of optimal individual therapy. The company also developed the PCR|ONE technology for rapid, automated infection detection, which was developed by Curiosity Diagnostics Sp. z o.o., a company in which 100% of shares were sold in August 2022 to the American company Bio-Rad Laboratories, Inc., for a total of up to 170 million USD (including 100 million USD as an upfront payment).

The BacterOMIC project was a semi-finalist in the 2019 American Association for Clinical Chemistry Disruptive Technology Competition. During the 7th Congress of Polish Capital, organized by Forbes Polska magazine, Scope Fluidics was awarded the title of Stock Company of the Year 2022. The company also won the Bulls and Bears of the Stock Market and Investors’ Parkiet award in the NewConnect Market Company of the Year 2022 category. Prof. Piotr Garstecki, co-founder, one of the largest shareholders, and CEO of Scope Fluidics S.A., secured third place in the prestigious 2022 Leaders of Polish Business Ranking, prepared by Forbes Polska magazine. Since 2017, Scope Fluidics S.A. has been listed on the NewConnect market. In January 2023, the company debuted on the main market of the Warsaw Stock Exchange, and in February, it became a part of the sWIG80 index.